NCT01621061

Brief Summary

High altitude pulmonary hypertension, a form of altitude illness that occurs in long-term residents at altitudes \>2500 m, is characterized by dyspnea, hypoxemia, impaired exercise performance and hypertension in the pulmonary circulation. Whether sleep related breathing disturbances, common causes of nocturnal hypoxemia in lowlanders, are also prevalent in highlanders and promote pulmonary hypertension in highlanders is unknown. Therefore, the current study will investigate whether highlanders with high altitude pulmonary hypertension have a greater prevalence of sleep apnea than healthy highlanders and lowlanders.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
125

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

June 13, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 15, 2012

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

May 15, 2014

Status Verified

May 1, 2014

Enrollment Period

1.5 years

First QC Date

June 13, 2012

Last Update Submit

May 14, 2014

Conditions

Keywords

high altitude illnesspulmonary hypertensionsleep apneahypoxia

Outcome Measures

Primary Outcomes (1)

  • Sleep related breathing disturbances

    Nocturnal oxygen saturation and apnea/hypopnea index

    4 months

Secondary Outcomes (10)

  • Pulmonary artery pressure

    4 months

  • Dyspnea

    4 months

  • Vigilance

    4 months

  • Exercise performance

    4 months

  • Pulmonary function

    4 months

  • +5 more secondary outcomes

Study Arms (3)

High altitude pulmonary hypertension

Highlanders with high altitude pulmonary hypertension

High altitude control

Healthy highlanders

Low altitude control

Healthy lowlanders

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Highlanders with high altitude pumonary hypertension living at an altitude of 2500-4000 m; healthy highlanders living at an altitude of 2500-4000 m; healthy lowlanders living at an altitude of \<1000 m.

You may qualify if:

  • high altitude pulmonary hypertension confirmed by clinical presentation and systolic pulmonary artery pressure \>50 mmHg measured by echocardiography at altitude of residence.
  • healthy subjects (high altitude controls)
  • Both genders
  • Age \>16 y
  • Kyrgyz ethnicity
  • born, raised and currently living at \>2500 m
  • healthy subjects currently living at \<1000 m (low altitude controls)

You may not qualify if:

  • Pulmonary hypertension from other causes, in particular from left ventricular failure as judged clinically and by echocardiography
  • excessive erythrocytosis
  • other coexistent disorders that may interfere with the cardio-respiratory system and sleep
  • regular use of medication that affects control of breathing
  • heavy smoking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Center for Cardiology and Internal Medicine

Bishkek, 720040, Kyrgyzstan

Location

MeSH Terms

Conditions

Pulmonary edema of mountaineersSleep Apnea SyndromesHypertension, PulmonaryHypoxia

Condition Hierarchy (Ancestors)

ApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesLung DiseasesHypertensionVascular DiseasesCardiovascular DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Konrad E Bloch, MD

    University of Zurich, Switzerland

    PRINCIPAL INVESTIGATOR
  • Talant Sooronbaev, MD

    National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 13, 2012

First Posted

June 15, 2012

Study Start

June 1, 2012

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

May 15, 2014

Record last verified: 2014-05

Locations